Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

A legfontosabb adatok

Ki végzi
W.L.Gore & Associates
Hol
Ann Arbor, Atlanta, Birmingham, Boston, Chicago, Cleveland, Columbus, Durham, Gainesville, Grand Rapids, Hackensack, Houston, Indianapolis, Los Angeles, Milwaukee, Morgantown, Palo Alto, Philadelphia, Pittsburgh, Plano, St Louis és Westchester (Egyesült Államok)Mind a 22 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
112 fő, tervezett
Kezdés
2025. szept. 22.
Várható befejezés
2031. szept. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • GORE® Ascending Stent Graft (ASG device)
A regiszteradat frissítve
2026. október 23.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 44 feltétel megnézéseKevesebb

Ki vehet részt

  • The subject is/has:
  • De novo Type A aortic dissection (≤30 days from symptom onset to index endovascular procedure) compatible with the treatment requirements of the ASG device
  • Primarily intended to be treated by placement of the ASG device in the ascending aorta. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator
  • Anatomic compatibility of the ascending aorta required for implanting the ASG device:; Proximal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium; Total aortic diameter between 27mm - 48mm iii. Landing zone cannot be heavily calcified or thrombosed. b) Distal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium; Adequate aortic length
  • The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:; ≥80 years of age; Body mass index (BMI) ≥ 35 kg/m2; History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised pulmonary function tests (PFT) on spirometry or other factors as determined by the Investigator); Prior Cardiac Surgery; Hostile Chest (VARC-2 Definition); Clinical Frailty Scale 3-7; Clinical malperfusion (head, gut, lower extremity); Transfusion is not possible (e.g., Jehovah's Witness); Renal Dialysis prior to aortic dissection; Chronic renal insufficiency (eGFR<60 without dialysis or other documented history of chronic kidney disease prior to dissection)
  • Age ≥18 years at time of informed consent signature
  • Adequate vascular access via transfemoral or retroperitoneal approach
  • Informed Consent Form (ICF) signed by the subject or legally authorized representative
  • Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows
  • The subject is/has:
  • De novo Type A aortic dissection (≤90 days from symptom onset until first study procedure) compatible with the treatment requirements of the ASG device alone or the ASG device in combination with the TBE device in the Zone 0 position
  • Primarily intended to be treated by placement of the ASG device in the ascending aorta or ASG device in combination with the TBE device in the ascending aorta and aortic arch. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator
  • Anatomic requirements for intended treatment with the ASG device alone or in combination with the TBE device; Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device alone) i. Proximal Aortic Landing Zone:; Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium; Total aortic diameter between 27mm - 48mm; Landing zone cannot be heavily calcified or thrombosed. ii. Distal Aortic Landing Zone:; <!-- -->; Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium; Adequate aortic length; Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device and TBE device) i. Proximal Aortic Landing Zone:; <!-- -->; Primary entry tear must be identified in Zone 0-5; Landing zone is native aorta; Primary entry tear location is ≥2cm distal to the most distal coronary artery ostium; Proximal landing zone must be ≥2cm in the ascending aorta; Landing zone cannot be heavily calcified or thrombosed; Total aortic landing zone diameter 27mm - 48mm. ii. Branch Vessel Landing Zone:; <!-- -->; Length of ≥2.5 cm proximal to first major branch vessel; Target branch vessel inner diameters of 11-18 mm; Target branch vessel landing zone must be in native vessel that cannot be heavily calcified or thrombosed; The distal 15mm landing zone cannot be dissected
  • The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:; ≥80 years of age; BMI ≥ 35 kg/m2; History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised PFTs on spirometry or other factors as determined by the Investigator); Prior Cardiac Surgery; Hostile Chest (VARC-2 Definition); Clinical Frailty Scale 3-9; Clinical malperfusion (head, gut, lower extremity); Transfusion is not possible (e.g., Jehovah's Witness); Renal Dialysis prior to aortic dissection; Chronic renal insufficiency (eGFR<60 without dialysis or other documented history of chronic kidney disease prior to dissection)
  • Age ≥18 years at time of informed consent signature
  • Adequate vascular access via transfemoral or retroperitoneal approach
  • Informed Consent Form (ICF) signed by the subject or legally authorized representative
  • Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows

Ki nem vehet részt

  • Participation in investigational drug or medical device study within one year of enrollment unless approved by the Sponsor
  • Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication)
  • Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 [HIT-2], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and/or state should be considered exclusion if treatment plan includes implant of a TBE device)
  • Catastrophic neurological complications in the 30 days prior to the dissection diagnosis (e.g., progressively worsening symptoms, coma, Glasgow Coma Scale <=8)
  • In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at any time prior to the initiation of the index endovascular procedure
  • Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication)
  • Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 [HIT-2], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and/or state should be considered exclusion if treatment plan includes implant of a TBE device)
  • Mechanical heart valve in the aortic position
  • Aortic insufficiency grade 3 or greater confirmed during TEE pre-implant
  • Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome)
  • Known history of drug abuse within one year of treatment which would affect the ability to obtain follow-up
  • Active infected aorta, mycotic aneurysm
  • Life expectancy <12 months due to presence of another comorbid condition
  • Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
  • Aortic fistula
  • Mechanical heart valve in the aortic position
  • Active infected aorta, mycotic aneurysm
  • Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
  • In circulatory shock (e.g., systolic blood pressure <80 mmHg without inotropes, base deficit > -10 mmol/L or -10 mEq/L) at any time prior to the initiation of the index endovascular procedure
  • Clinical or radiographic signs of bowel infarction, gastrointestinal hemorrhage, or bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis) at any time prior to the initiation of the index endovascular procedure
  • The subject is/has:
  • Indwelling intravascular device that would interfere with or result in contact with planned repair (e.g., contiguous arch graft, LVAD, TAVR device in continuity with aortic tear)
  • Pregnant at time of procedure
  • Coronary malperfusion
  • The subject is/has:
  • Pregnant at time of procedure

Helyszínek itt: Egyesült Államok

  • University of MichiganAnn Arbor, Egyesült Államok
  • Emory University School of MedicineAtlanta, Egyesült Államok
  • University of Alabama at BirminghamBirmingham, Egyesült Államok
  • Massachusetts General HospitalBoston, Egyesült Államok
  • Northwestern MedicineChicago, Egyesült Államok
  • Cleveland ClinicCleveland, Egyesült Államok
  • Ohio Health Research InstituteColumbus, Egyesült Államok
  • Duke University Medical CenterDurham, Egyesült Államok
  • University of FloridaGainesville, Egyesült Államok
  • Corewell Health SystemGrand Rapids, Egyesült Államok
  • Hackensack Medical CenterHackensack, Egyesült Államok
  • The Methodist Hospital - HoustonHouston, Egyesült Államok
  • Indiana UniversityIndianapolis, Egyesült Államok
  • University of Southern CaliforniaLos Angeles, Egyesült Államok
  • Medical College of WisconsinMilwaukee, Egyesült Államok
  • WVU MedicineMorgantown, Egyesült Államok
  • The Stanford HospitalPalo Alto, Egyesült Államok
  • Hospital of the University of PennsylvaniaPhiladelphia, Egyesült Államok
  • University of Pittsburgh Medical CenterPittsburgh, Egyesült Államok
  • Baylor Research InstitutePlano, Egyesült Államok
  • Washington University School of Medicine - St. LouisSt Louis, Egyesült Államok
  • Westchester Medical CenterWestchester, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

A vizsgálat 2 csoportja

  • PrimaryA vizsgált kezelés

    A hypothesis driven analysis of the safety and effectiveness of the GORE® Ascending Stent Graft (ASG) device alone in the ascending aorta. Dissection chronicity in the primary arm must be 30 days or less from symptom onset to index endovascular procedure.

    Kezelés: GORE® Ascending Stent Graft (ASG device)

  • SecondaryA vizsgált kezelés

    Descriptive analysis of use of the ASG device in patients who are not eligible for treatment in the primary arm. Dissection chronicity up to 90 days from symptom onset until the first study procedure is allowed in the secondary arm.

    Kezelés: GORE® Ascending Stent Graft (ASG device)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
A regiszteradat frissítve
2026. október 23.